线粒体靶向药物治疗缺血性心脏病的研究进展

摘要

缺血性心脏病是全球范围内导致人类死亡的主要疾病之一.溶栓和经皮冠状动脉介入术是目前治疗缺血性心脏病的主要方法,可及时恢复心肌灌注、避免心肌梗死.研究证实,在心肌缺血再灌注过程中采取一定保护措施可有效减轻心肌缺血再灌注损伤.线粒体功能紊乱是心肌缺血及再灌注损伤的重要病理学基础,故线粒体可作为抗心肌缺血再灌注损伤的重要靶点.尽管实验室研究已发现多种线粒体靶向药物可有效减轻心肌缺血再灌注损伤,但目前顺利通过临床试验的药物仍较少,线粒体作为抗心肌缺血再灌注损伤的重要靶点仍未被充分利用.本文主要综述了线粒体靶向药物治疗缺血性心脏病的研究进展.%Ischemic heart disease is one of major diseases that leading to human death in global.Thrombolysis and percutaneous coronary intervention are the main therapeutic strategies for ischemic heart disease at present,which can timely recover the myocardial perfusion and avoid myocardial infarction.Many studies confirmed that,some protective measures during myocardial ischemia reperfusion can effectively relive the myocardial ischemia reperfusion injury.Mitochondrial dysfunction is involved in myocardial ischemia and myocardial ischemia reperfusion injury,thus can be served as a target for treating myocardial ischemia reperfusion injury.Laboratory studies showed that,a variety of mitochondrion-targeted drugs can effectively relive the myocardial ischemia reperfusion injury,but most mitochondrion-targeted drugs can not get through the clinical trials,meaning mitochondrion-targeted drugs still have huge developing space.This paper reviewed the progress on mitochondrion-targeted drugs in treating ischemic heart disease.